AGYTF News 0.3573 Allergy Therapeutics (AGYTF)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Allergy Therapeutics (AGYTF) 0.3573 $AGYTF

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013
M2 - Thu Feb 20, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/mr7rjr/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013" report to their offering. 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Scope - A snapshot of the global therapeutic scenario for Allergic Rhino-Conjunctivitis. - A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Allergic Rhino-Conjunctivitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Unknown Stage Products Drug Profiles Pollinex Quattro Grass - Drug Profile MK-7243 - Drug Profile MK-3641 - Drug Profile grass pollen allergen extract - Drug Profile Pollinex Quattro Grass - Drug Profile MK-8237 - Drug Profile Grass Pollen Allergoid - Drug Profile Olea Europaea Pollen Extract - Drug Profile Modified Allergen Extract - Drug Profile AL-0704rP - Drug Profile Acaroid - Drug Profile Depigoid Birch - Drug Profile Recombinant Birch Pollen Allergen - Drug Profile Ragweed Pollen Extract - Drug Profile Avanz Phleum Pratense - Drug Profile CYT-003-QbG10 - Drug Profile gpASIT TM - Drug Profile ALK Birch Pollen Vaccine - Drug Profile Osiris - Drug Profile Phleum Pratense - Drug Profile JRC-LAMP Vax - Drug Profile bilastine - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned BioTech Tools ALK-Abello A/S FAES Farma SA Allergy Therapeutics plc Stallergenes S.A. Cytos Biotechnology AG Allergopharma Joachim Ganzer KG Greer Laboratories, Inc. Laboratorios LETI S.L. Immunomic Therapeutics, Inc. Bial - Portela & Ca, S.A. Roxall Medizin GmbH For more information visit http://www.researchandmarkets.com/research/mr7rjr/allergic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Cedar Pollen Allergy - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 12, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3sxtk/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2013" report to their offering. 'Cedar Pollen Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cedar Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy. Scope - A snapshot of the global therapeutic scenario for Cedar Pollen Allergy. - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cedar Pollen Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cedar Pollen Allergy Overview Therapeutics Development Cedar Pollen Allergy - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Cedar Pollen Allergy - Therapeutics Assessment Drug Profiles TO-194SL - Drug Profile TAC-201 - Drug Profile Cry J1-galactomannan Conjugate - Drug Profile JRC-LAMP Vax - Drug Profile TO-206 - Drug Profile Pollinex Quattro Japanese Cedar - Drug Profile RGI-1001 - Drug Profile Japanese Cedar Pollen Tablet - Drug Profile Japanese Cedar Hypoallergenic Vaccine - Drug Profile AllerJ - Drug Profile Cedar Pollen Vaccine - Drug Profile Vaccine For Japanese Cedar Pollen Allergy - Drug Profile Featured News & Press Releases Appendix Companies Mentioned Taiho Pharmaceutical Co., Ltd. Allergy Therapeutics plc Stallergenes S.A. Torii Pharmaceutical Co., Ltd. Anergis SA REGiMMUNE Corporation Immunomic Therapeutics, Inc. Biomay AG Adiga Life Sciences Inc. For more information visit http://www.researchandmarkets.com/research/f3...dar_pollen About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Grass Pollen Allergy - Pipeline Review, H2 2013
M2 - Wed Dec 11, 3:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3m4p4/grass_pollen) has announced the addition of the "Grass Pollen Allergy - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Grass Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Grass Pollen Allergy. Scope - A snapshot of the global therapeutic scenario for Grass Pollen Allergy. - A review of the Grass Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Grass Pollen Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - ALK-Abello - ANERGIS - Allergopharma Joachim Ganzer - Allergy Therapeutics - Bial - Portela & Ca - Biomay - Circassia - Laboratorios LETI - Stallergenes For more information visit http://www.researchandmarkets.com/research/f3...ass_pollen About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

Research Report: Ragweed Allergy - Pipeline Review, H2 2013
M2 - Tue Dec 10, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/wdfhh2/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H2 2013" report to their offering. 'Ragweed Allergy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ragweed Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ragweed Allergy. Scope - A snapshot of the global therapeutic scenario for Ragweed Allergy. - A review of the Ragweed Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ragweed Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ragweed Allergy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ragweed Allergy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned ALK-Abello A/S Allergy Therapeutics plc Stallergenes S.A. Circassia Holdings Ltd. ANERGIS SA Immunomic Therapeutics, Inc. Biomay AG For more information visit http://www.researchandmarkets.com/research/wd...ed_allergy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Cedar Pollen Allergy - Pipeline Review, H1 2013
M2 - Tue Jul 16, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wj83qr/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2013" report to their offering. 'Cedar Pollen Allergy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cedar Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understand

Ragweed Allergy - Global Pipeline Review Report, H1 2013 Edition
M2 - Mon Jun 10, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpdwr8/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H1 2013" report to their offering. 'Ragweed Allergy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ragweed Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ragweed Allergy. Scope - A snapshot of the global therapeutic scenario for Ragweed Allergy. - A review of the Ragweed Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ragweed Allergy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Ragweed Allergy Therapeutics Development - ALK-Abello A/S - Allergy Therapeutics plc - Circassia Holdings Ltd. - ANERGIS SA - Immunomic Therapeutics, Inc. - Biomay AG For more information visit http://www.researchandmarkets.com/research/zp...ed_allergy

Global Birch Pollen Allergy Report - Pipeline Review, H1 2013 Edition
M2 - Fri Jun 07, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6mnpzk/birch_pollen) has announced the addition of the "Birch Pollen Allergy - Pipeline Review, H1 2013" report to their offering. 'Birch Pollen Allergy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Birch Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy. Scope - A snapshot of the global therapeutic scenario for Birch Pollen Allergy. - A review of the Birch Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of mono

Global Allergic Rhino-Conjunctivitis Report - Pipeline Review, H1 2013 Edition
M2 - Thu Jun 06, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vm88b/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2013" report to their offering. 'Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Scope - A snapshot of the global therapeutic scenario for Allergic Rhino-Conjunctivitis. - A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012 Gives a Clear Account of the Market
M2 - Mon Feb 18, 8:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/cdgh58/allergic) has announced the addition of Global Markets Direct's new report "Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Allergic Rhino-Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets D

Food Allergy - Pipeline Review: Latest updates and review of key players
M2 - Wed Jan 09, 4:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/q4bl3l/food_allergy) has announced the addition of Global Markets Direct's new report "Food Allergy - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Food Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Food Allergy. Food Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Food Allergy. - A review of the Food Allergy products under development by companies and universities/research institutes based on informa

Paladin Labs Acquires Distribution Rights to Pollinex(R)-R in Canada
Marketwire - Tue Jan 08, 3:11PM CST
Paladin Labs Inc. (TSX: PLB) announced today that it has entered into an exclusive Canadian distribution agreement with Allergy Therapeutics plc (AIM: AGY) for Pollinex(R)-R (modified ragweed tyrosine adsorbate), an allergy vaccine for the treatment of allergic rhinitis due to ragweed pollen. In addition, Paladin also received an option to acquire distribution rights to Pollinex(R)-R in Sub-Saharan Africa. Under the agreement Paladin will co-promote the product with Takeda Canada Inc. for the first eight months before taking over all selling and distribution activities. Financial terms of the agreement were not disclosed.

Birch Pollen Allergy - Pipeline Review, H2 2012
M2 - Thu Dec 20, 2:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/k9dt94/birch_pollen) has announced the addition of Global Markets Direct's new report "Birch Pollen Allergy - Pipeline Review, H2 2012" to their offering. 'Birch Pollen Allergy - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Birch Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy. Birch Pollen Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Reasons to buy - Identify and understand important

Ragweed Allergy - Pipeline Review, H2 2012
M2 - Thu Dec 20, 2:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/9jdn28/ragweed_allergy) has announced the addition of Global Markets Direct's new report "Ragweed Allergy - Pipeline Review, H2 2012" to their offering. 'Ragweed Allergy - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ragweed Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ragweed Allergy. Ragweed Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Ragweed Allergy
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thanksgiving Kitchen Safety Is No Place for Autopilot

Updated Category News Views 61

Steam, chatter, and one forgotten burner can turn a holiday meal ugly in a hurry. The Consumer Product Safety Commission’s Nov. 19, 2026 reminder lands on a point that should not need repeating, yet plainly does: Thanksgiving kitchens demand attention, not casual optimism. This is not about ruining anybody’s celebration with a lecture. It is about recognizing that a...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 130

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Chainlink, UBS Take $2 Trillion Notes Toward Onchain

Updated Category News Views 74

Paperwork is a lousy moat when a bank can automate the mess. Chainlink and UBS are putting that proposition to work in structured notes, a market with more than $2 trillion in outstanding notional and, frankly, an awful lot of operational clutter. Their production solution uses the Chainlink Runtime Environment, or CRE, to connect UBS systems, smart contracts, market data...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 35

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 47

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 58

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 60

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
RBC Signals Gets $10 Million to Push Space Infrastructure

Updated Category News Views 85

Ground stations are the unglamorous plumbing of the space economy, and somebody finally put fresh capital behind the wrench. RBC Signals says it has received a $10 million strategic growth investment led by Washington Harbour Partners, aimed at enlarging its government-services operation and pushing several newer space-connectivity tools toward commercial use. This is a...

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 195

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading

Top 5 Most Recently Viewed Articles

Boots Group Wraps Up Consent Solicitation for Notes

Updated Category News Views 183

Consent Solicitation's Critical Role in Acquisition No time for dawdling—Boots Group's gathered up their consent cards for hefty senior secured notes, and we're talking close to a billion smackers here. It's a bold move to grease the wheels on looming acquisition maneuvers. We're looking at a €650 million and a £375 million stack of senior secured notes patiently...

Continue Reading
HUB Cyber Security Ltd. Welcomes Romke E. de Haan III

Updated Category News Views 120

HUB Cyber Security Ltd. Strengthens Leadership with New Appointment HUB Cyber Security Ltd. (NASDAQ: HUBC), a frontrunner in AI-driven cybersecurity solutions, has made a significant move by appointing Romke E. de Haan III as the Head of its Cybersecurity Strategy and Innovation Division. This pivotal role is expected to bolster the company's position within the North...

Continue Reading
Lisk EMpower Fund: Empowering Founders in Web3 Ventures

Updated Category News Views 177

Lisk EMpower Fund: A New Horizon for Web3 Startups The recently launched Lisk EMpower Fund is designed to support post-incubation Web3 startups in rapidly evolving markets, particularly in regions such as Africa, Latin America, and Southeast Asia. This initiative aims to bridge the gap in capital availability, providing opportunities for founders to achieve significant...

Continue Reading
BMO Capital Raises Datadog Price Target on Strong Revenue Outlook

Updated Category News Views 164

BMO Capital Shows Confidence in Datadog's Growth Recently, BMO Capital Markets demonstrated a strong belief in Datadog Inc (NASDAQ: DDOG), which operates a cloud-based monitoring and analytics platform. The firm raised its price target for the stock from $132.00 to $135.00 while maintaining an Outperform rating, reflecting their confidence in the company's ability to...

Continue Reading
Guru4Invest Introduces Revolutionary Security Upgrades

Updated Category News Views 555

Guru4Invest Strengthens Client Security with New Protocols In a significant move to bolster client safety and data integrity, Guru4Invest has rolled out advanced security protocols aimed at enhancing the protection of customer accounts and sensitive information. This decision reflects the company's steadfast commitment to security within the trading sector, showcasing...

Continue Reading